If you have been reading about alpha-MSH and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
=== EC 1.13.12 With incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases) === EC 1.13.12.1: arginine 2-monooxygenase EC 1.13.12.2: lysine 2-monooxygenase EC 1.13.12.3: tryptophan 2-monooxygenase EC 1.13.12.4: lactate 2-monooxygenase EC 1.13.12.5: Renilla-type luciferase EC 1.13.12.6: Cypridina-luciferin 2-monooxygenase EC 1.13.12.7: firefly luciferase EC 1.13.12.8: Watasenia-luciferin 2-monooxygenase EC 1.13.12.9: phenylalanine 2-monooxygenase EC 1.13.12.10: Reaction covered by EC 1.14.13.59, L-lysine 6-monooxygenase (NADPH) EC n1.13.12.11: The activity is due to EC 1.14.13.8, flavin-containing monooxygenase EC 1.13.12.12: transferred to EC 1.13.11.67, 8-apo-β-carotenoid 14′,13′-cleaving dioxygenase EC 1.13.12.13: Oplophorus-luciferin 2-monooxygenase EC 1.13.12.14: Now EC 1.14.13.122, chlorophyllide-a oxygenase EC 1.13.12.15: 3,4-dihydroxyphenylalanine oxidative deaminase EC 1.13.12.16: nitronate monooxygenase EC 1.13.12.17: dichloroarcyriaflavin A synthase EC 1.13.12.18: dinoflagellate luciferase EC 1.13.12.19: 2-oxoglutarate dioxygenase (ethene-forming) EC 1.13.12.20: noranthrone monooxygenase EC 1.13.12.21: tetracenomycin-F1 monooxygenase EC 1.13.12.22: deoxynogalonate monooxygenase EC 1.13.12.23: 4-hydroxy-3-prenylbenzoate synthase EC 1.13.12.24: calcium-regulated photoprotein
== Diagnosis == Craniocervical instability is usually diagnosed through neuro-anatomical measurement using radiography. Digital Motion X-ray is considered the most accurate method. Upright magnetic resonance imaging, supine magnetic resonance imaging, CT scan, and flexion and extension x-rays may also be used but are far less accurate and have a much higher potential for false negatives. The measurements to diagnose craniocervical instability are:
Macro-creatine kinase (macro-CK) is a macroenzyme, an enzyme of high molecular weight and prolonged half-life found in human serum. It is one of the most common macroenzymes. Macro-CK type 1 is a complex formed by one of the creatine kinase isoenzyme types, typically CK-BB, and antibodies; typically IgG, sometimes IgA, rarely IgM. Macro-CK type 2 is formed from mitochondrial CK polymer. Macro-CK type 1 has been associated with autoimmune and other chronic conditions. Macro-CK type 2 has been associated with malignancy. Macro-CK has been implicated as a source of interference in interpretation of medical labs.
=== Mechanism of action === Isotretinoin's exact mechanism of action is unknown, but several studies have shown that isotretinoin induces apoptosis (programmatic cell death) in various cells in the body. Cell death may be instigated in the meibomian glands, hypothalamic cells, hippocampus cells and—important for treatment of acne—in sebaceous gland cells. Isotretinoin has a low affinity for retinoic acid receptors (RAR) and retinoid X receptors (RXR), but may be converted intracellularly to metabolites that act as agonists of RAR and RXR nuclear receptors. One study suggests the drug amplifies production of neutrophil gelatinase-associated lipocalin (NGAL) in the skin, which has been shown to reduce sebum production by inducing apoptosis in sebaceous gland cells, while exhibiting an antimicrobial effect on Cutibacterium acnes. The drug decreases the size and sebum output of the sebaceous glands. Isotretinoin is the only available acne drug that affects all four major pathogenic processes in acne, which distinguishes it from alternative treatments (such as antibiotics) and accounts for its efficacy in severe, nodulocystic cases.
Sources: en.wikipedia.org
Rindo Azami (阿左美 竜胆, Azami Rindō) Voiced by: Taku Yashiro (Japanese); Lee George (English) The Agent of Autumn's Guard. He treats his job like a business, without letting his emotions get in the way. Those around him don't see it that way. He doesn't realize it, but he's overprotective of Nadeshiko.
Simon enters the previously chained-up apartment and, after a long hallway where he hears a doctor describing an encounter with his patient and being attacked yet again, finds the fuses. While attempting to retrieve the fuses again to open a gate for a train, he enters another nightmare where he is chased through a maze by monsters hanging from the ceiling, escaping through a door that opens back up to a completely different hallway. After boarding the train, Simon is attacked by monsters yet again, and the train eventually crashes and derails, causing him to lose all of his belongings. As the train is about to fall off a cliff, Simon narrowly escapes and finds himself in a dark forest. Deep in the forest, Simon discovers an asylum as the doctor enters. Simon finds the doctor behind a gate where the doctor orders him to hand him a new gun in exchange for letting him pass. Simon can either oblige or refuse, but regardless, the doctor ends up betraying Simon and shoots him (with a greater penalty to maximum health if Simon complied). Simon eventually kills the doctor after a gunfight. Simon leaves the forest and rows a boat across a lake to his hometown. He finally reaches his house and expects his mother to be waiting for him, but the house is empty. He enters his bedroom and finds a book. Through a flashback, the player finds out that the entire story was a figment of Simon's imagination. After the car crash, Simon became reliant on a wheelchair. Depressed, his therapist (who was the doctor in the game) advised him to document his feelings in a book.
BRI1-associated receptor kinase 1 (BAK1) is an LRR-RLK found in A. thaliana, which has been proposed to function as an adaptor protein that is required for the proper functioning of other RLKs. Yeast two-hybrid assays have shown that AtPEPR1 and its closest analog, AtPEPR2, interact with BAK1.
After James Chadwick discovered the neutron in 1932, Irène Curie and Frédéric Joliot irradiated aluminium foil with alpha particles. They found that this results in a short-lived radioactive isotope of phosphorus. They noted that positron emission continued after the neutron emissions ceased. Not only had they discovered a new form of radioactive decay, they had transmuted an element into a hitherto unknown radioactive isotope of another, thereby inducing radioactivity where there had been none before. Radiochemistry was now no longer confined to certain heavy elements, but extended to the entire periodic table. Chadwick noted that being electrically neutral, neutrons could penetrate the atomic nucleus more easily than protons or alpha particles. Enrico Fermi and his colleagues in Rome picked up on this idea, and began irradiating elements with neutrons. The radioactive displacement law of Fajans and Soddy said that beta decay causes isotopes to move one element up on the periodic table, and alpha decay causes them to move two down. When Fermi's group bombarded uranium atoms with neutrons, they found a complex mix of half-lives. Fermi therefore concluded that the new elements with atomic numbers greater than 92 (known as transuranium elements) had been created. Meitner and Hahn had not collaborated for many years, but Meitner was eager to investigate Fermi's results. Hahn, initially, was not, but he changed his mind when Aristid von Grosse suggested that what Fermi had found was an isotope of protactinium.
=== Australia === As of July 2019, beak trimming is only banned in the Australian Capital Territory by means of the Animal Welfare Act 1992 (ACT) s 9C. It is currently debated in parliament whether debeaking should be banned in Victoria and New South Wales. A 2019 Voiceless report recommended the NSW Parliament to prohibit debeaking and instead '[introduce] enriched environmental conditions, such as litter and suitable range areas [to] encourage interaction and mental stimulation for hens. Better nutrition, lighting and parasite management may also help reduce injurious pecking.' In a 2015 survey conducted by the Humane Society International Australia, 91% of respondents stated that free range egg boxes should display whether the hens had undergone beak trimming.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.